AOD-9604
hGH fragment 177–191 analogue
Modified growth-hormone fragment that failed to show meaningful weight loss in phase 2b trials.
Not FDA-approved. Not approved as a drug. Granted GRAS status as a food ingredient in the US (2014). Prohibited by WADA. This page describes research and public discussion; it is not a recommendation to use.
Overview
AOD-9604 was developed in Australia as an anti-obesity drug based on the lipolytic region of human growth hormone. Early trials were promising, but a larger 2007 trial found no significant weight loss versus placebo and development for obesity was stopped.
Mechanism of action
Proposed to stimulate lipolysis and inhibit lipogenesis without GH's effects on IGF-1 or blood glucose.
Benefits & evidence ratings
Dosing
Doses show what has been studied or discussed — not guidance. Always follow your prescriber.
| Source | Dose | Frequency | Duration | Route |
|---|---|---|---|---|
Phase 2b obesity trial B Human clinical data No significant effect vs placebo at study end. | 0.25–1 mg | Once daily | 24 weeks | Oral |
Online protocols D Anecdotal / community | ~250–500 mcg | Daily | 8–12 weeks | Subcutaneous |
Clinical trials & studies
- Human study2013Safety and tolerability of the hGH fragment AOD9604 (Obesity Research)
Six randomized trials (n≈900); safety profile similar to placebo.
Safety
Side effects
- Generally similar to placebo in trials
- Injection-site reactions (when injected)
Contraindications
- Pregnancy
- Competitive athletes (WADA-prohibited)
Interactions
- None well characterized
Long-term safety
Not studied beyond ~24 weeks.
Regulatory status
Unapproved / research
Not approved as a drug. Granted GRAS status as a food ingredient in the US (2014). Prohibited by WADA.
FAQ
Commonly discussed alongside
Listing a combination does not mean it has been studied or is safe.
Considering a GLP-1 for weight loss?
Compare licensed telehealth providers by true monthly cost and care quality.
See your top 3 matches